XML 50 R34.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

REVENUES - Summary of Disaggregation of Revenues (Details) - USD ($) $ in Millions | 3 Months Ended
--- | ---
Mar. 31, 2024 | Mar. 31, 2023
Disaggregation of Revenue [Line Items] |  |
Total revenues | $ 6,686 | $ 6,352
U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 4,633 | 4,452
Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 1,159 | 1,079
Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 894 | 821
Total product sales |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 6,647 | 6,306
Total product sales | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 4,609 | 4,434
Total product sales | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 1,144 | 1,053
Total product sales | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 894 | 819
Total HIV |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 4,342 | 4,190
Total HIV | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 3,405 | 3,364
Total HIV | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 596 | 528
Total HIV | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 342 | 298
Biktarvy |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 2,946 | 2,677
Biktarvy | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 2,315 | 2,161
Biktarvy | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 365 | 304
Biktarvy | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 265 | 212
Descovy |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 426 | 449
Descovy | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 371 | 395
Descovy | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 26 | 25
Descovy | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 29 | 29
Genvoya |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 403 | 501
Genvoya | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 332 | 417
Genvoya | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 49 | 55
Genvoya | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 21 | 29
Odefsey |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 310 | 317
Odefsey | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 223 | 230
Odefsey | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 76 | 76
Odefsey | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 11 | 11
Revenue share - Symtuza |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 141 | 138
Revenue share - Symtuza | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 104 | 98
Revenue share - Symtuza | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 33 | 36
Revenue share - Symtuza | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 3 | 4
Other HIV |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 117 | 108
Other HIV | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 60 | 62
Other HIV | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 45 | 32
Other HIV | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 12 | 13
Total Liver Disease |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 737 | 675
Total Liver Disease | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 385 | 318
Total Liver Disease | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 137 | 140
Total Liver Disease | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 215 | 217
Sofosbuvir/Velpatasvir |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 405 | 385
Sofosbuvir/Velpatasvir | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 248 | 204
Sofosbuvir/Velpatasvir | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 79 | 90
Sofosbuvir/Velpatasvir | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 78 | 90
Vemlidy |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 225 | 199
Vemlidy | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 95 | 87
Vemlidy | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 11 | 9
Vemlidy | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 119 | 103
Other Liver Disease |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 107 | 91
Other Liver Disease | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 42 | 27
Other Liver Disease | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 47 | 41
Other Liver Disease | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 19 | 23
Veklury |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 555 | 573
Veklury | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 315 | 252
Veklury | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 70 | 111
Veklury | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 169 | 209
Total Oncology |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 789 | 670
Total Oncology | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 431 | 431
Total Oncology | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 262 | 202
Total Oncology | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 96 | 37
Total Cell Therapy |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 480 | 448
Total Cell Therapy | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 225 | 269
Total Cell Therapy | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 195 | 148
Total Cell Therapy | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 60 | 31
Tecartus |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 100 | 89
Tecartus | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 55 | 59
Tecartus | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 36 | 27
Tecartus | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 8 | 3
Yescarta |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 380 | 359
Yescarta | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 170 | 210
Yescarta | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 158 | 121
Yescarta | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 52 | 28
Trodelvy |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 309 | 222
Trodelvy | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 206 | 162
Trodelvy | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 68 | 54
Trodelvy | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 36 | 6
Total Other |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 224 | 199
Total Other | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 73 | 69
Total Other | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 79 | 72
Total Other | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 71 | 58
AmBisome |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 144 | 116
AmBisome | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 14 | 6
AmBisome | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 70 | 60
AmBisome | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 60 | 49
Other |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 80 | 83
Other | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 59 | 62
Other | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 9 | 12
Other | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 12 | 9
Royalty, contract and other revenues |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 39 | 46
Royalty, contract and other revenues | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 23 | 18
Royalty, contract and other revenues | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | 15 | 26
Royalty, contract and other revenues | Rest of World |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues | $ 1 | $ 2

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=gild_OtherInternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsRevenueShareSymtuzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsOtherHIVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_LiverDiseaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_LiverDiseaseProductsSofosbuvirVelpatasvirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_LiverDiseaseProductsVemlidyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_LiverDiseaseProductsOtherLiverDiseaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_VekluryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OncologyProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_CellTherapyProductsTotalCellTherapyProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_CellTherapyProductsTecartusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_CellTherapyProductsYescartaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_TrodelvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsTotalOtherProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |